Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies
Recently, attention has increasingly centered on non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors application. Numerous clinical studies have underscored the potential of immunotherapy in treating resectable NSCLC, highlighting its role in improving patient outcomes. However, des...
Saved in:
Main Authors: | Yuzhu Chen, Fei Qi, Chenhao Sun, Peng Jiang, Xiangyu Xue, Xiaomei Yang, Xiaomi Li, Xin He, Yishuo Wang, Tongmei Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-01-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359241312501 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report
by: Yichen Dong, MD, et al.
Published: (2025-01-01) -
Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC
by: Sebastian Kraus
Published: (2024-10-01) -
Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy
by: Jie Yang, et al.
Published: (2024-07-01) -
Characterization of the genomic landscape in liver oligometastatic NSCLC
by: Rongxin Liao, et al.
Published: (2025-01-01) -
Efficacy and safety of neoadjuvant chemoimmunotherapy and chemotherapy in patients with potentially resectable stage IIIA/IIIB NSCLC: a retrospective study
by: Yuchen Wang, et al.
Published: (2025-01-01)